BUSINESS● LOW2h ago · Sep 25, 2026, 6:19 PM
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation
Seeking Alpha Tech · global
Ligand Pharma was rated Outperform by Barclays due to its biopharma royalty aggregation strategy. This indicates a positive assessment of the company's financial model and potential.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS13m agoNeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83Seeking Alpha TechBUSINESS17m agoFederal Reserve Board announces approval of application by Peoples Bancorp Inc.Federal Reserve